RANDOMIZED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE 143

被引：243

作者：

Reardona, D. A. ^{[1
,2
]}

Omuroa, A. ^{[3
]}

Brandes, A. A. ^{[4
]}

Rieger, J. ^{[5
,6
]}

Wick, A. ^{[7
]}

Sepulveda, J. ^{[8
]}

Phuphanich, S. ^{[9
]}

de Souza, P. ^{[10
]}

Ahluwalia, M. S. ^{[11
]}

Lim, M. ^{[12
]}

Vlahovicb, G. ^{[13
]}

Sampsonb, J. ^{[13
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] AUSL IRCCS Inst Neurol Sci, Bologna, Italy

[5] Klinikum Goethe Univ, Frankfurt, Germany

[6] Univ Tubingen, Tubingen, Germany

[7] Heidelberg Univ, Natl Ctr Tumor Dis, Neurol Clin, Heidelberg, Germany

[8] Hosp Univ 12 Octubre, Madrid, Spain

[9] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[10] Univ Western Sydney, Sch Med, Liverpool, NSW, Australia

[11] Cleveland Clin, Cleveland, OH 44106 USA

[12] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA

[13] Duke Univ, Med Ctr, Durham, NC USA

来源：

关键词：

D O I：

10.1093/neuonc/nox036.071

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OS10.3

引用

页码：21 / 21

页数：1